MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make cardiovascular disease curable and preventable.
MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease Read More »
